The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]
, 2018 Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John +8 more
core +1 more source
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma [PDF]
Biochemical Pharmacology, 2011 The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has revolutionized the understanding of melanoma biology and provided new strategies for the therapeutic management of this deadly disease. Highly potent small molecule inhibitors of BRAF are now showing great promise as a novel therapeutic strategy for melanomas ...
Inna V, Fedorenko +2 more
openaire +2 more sources
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. [PDF]
PLoS ONE, 2012 Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings.
Nathan V Lee +11 more
doaj +1 more source
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated [PDF]
Journal of Translational Medicine, 2020 Abstract Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation. DNA and RNA mutation status were assessed in 15 melanoma cell lines by Sanger sequencing and RNA-seq.
Al Hashmi, Muna +16 more
openaire +5 more sources
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]
, 2020 With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed +4 more
core
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers [PDF]
Drugs, 2018 The mitogen activated protein kinase/extracellular signal-related kinase (MAPK/ERK) signaling pathway serves an integral role in growth, proliferation, differentiation, migration, and survival of all mammalian cells. Aberrant signaling of this pathway is often observed in several types of hematologic and solid malignancies.
Jaquelyn N. Sanchez +2 more
openaire +2 more sources
Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
SAGE Open Medical Case Reports, 2019 Metastatic melanoma is an aggressive malignancy. Survival can be increased with the combination of BRAF and MEK inhibition. BRAF inhibitor-induced cutaneous toxicities can be attenuated with MEK inhibition.
Marco AJ Iafolla +3 more
doaj +1 more source
Cell Death and Disease, 2022 The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of thyroid cancer (TC), and finding more effective multitarget combination therapies may be an important solution.
Linfei Hu +15 more
doaj +1 more source
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. [PDF]
, 2018 Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important regulatory molecules.
Burlingame, Alma +18 more
core +1 more source
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. [PDF]
, 2014 BackgroundIn melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling.
Atefi, Mohammad S +13 more
core +1 more source